Grant awarded as part of UK government’s £46 million international COVID-19 prevention and research package Test will support global efforts to prevent further spread of COVID-19 by enabling rapid diagnosis at the point-of-need Funding will also initiate Mologic’s research for novel vaccine candidates Bedfordshire, UK, 6th March 2020: Mologic [...]
Project aims to facilitate early diagnosis and support efforts to stop the Ebola Virus Disease epidemic Rapid point-of-need test critical to boosting surveillance and response to global viral outbreaks Partnership builds on BIOASTER’s early R&D during the 2014-2016 Ebola outbreak Bedfordshire, UK, 25 February 2020: Mologic Ltd, a [...]
BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation to develop Onchocerciasis advanced rapid diagnostic with Mologic Ltd Lyon, January 07th, 2020 BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, today announced it has received a grant in the field of diagnosis of Neglected [...]
Mologic launches clinical trial for validation of point-of-care COPD exacerbation alert system COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD Headstart is a non-invasive self-test that detects lung biomarkers in the urine Observational, multi-centre validation trial carried out in collaboration [...]
Sherlock Biosciences and Mologic Establish Strategic Partnership to Develop Instrument-free Molecular Diagnostic Tests Collaboration facilitated by the Bill & Melinda Gates Foundation through an expansion of an existing grant to Mologic Combines expertise in nucleic acid sensing with [...]
Being recognised as a company pushing the boundaries of high sensitivity lateral flow technology, Charlton Morris Life Science recently visited Mologic to speak with our Co-Founder and Chief Scientific Officer, Professor Paul Davis, the originator of the Clearblue pregnancy test, the world’s first commercial application of lateral flow technology. [...]
Sep 20, 2019 | Leo O'Connor NEW YORK – Mologic is developing a multimarker point-of care diagnostic test using lateral flow technology that it anticipates launching in Europe next year. The diagnostic test, which is being evaluated as part of a University College London Hospitals (UCLH) study, is part [...]
Study aims to develop a rapid point-of-care diagnostic based on multiple biomarkers to detect emergent sepsis Observational study led by Mervyn Singer, Professor of Intensive Care Medicine and Dr David Brealey, Consultant in Intensive Care Bedfordshire, UK, 13 September 2019: Mologic Ltd, a leading developer of lateral flow and [...]
Calling all diagnostics innovators: A competition for you! If you have an interesting idea or marker for a new diagnostic test then enter the GE European Whatman Dx competition co-sponsored by Mologic. The winner will receive a 3 day coaching engagement with renowned [...]
NEW YORK (360Dx) – British diagnostics company Mologic has completed development of a next-generation lateral flow testing platform that it claims improves sensitivity significantly. The Bedford, UK-based firm is also working with a new center in Dakar, Senegal, that will deploy new tests based on the platform to support [...]
Visually-read device delivers up to 1,000-fold improvement in sensitivity to support surveillance and elimination efforts of global epidemics Since 2016, the Bill & Melinda Gates Foundation has committed $9.7 million to establish and accelerate the CARD technology programme Bedfordshire, UK, 7 May 2019: Mologic Ltd, a leading developer of [...]
Strengthens team as part of continued international expansion Bolsters US presence with the opening of subsidiary in Boston, MA Doubles device manufacturing capacity in UK Bedfordshire, UK, 1 April 2019: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, services and products, today announced it [...]
